This article was originally published on Feb 28, 2020, and has been updated on Apr 13, 2020.

Coronavirus disease 19 (COVID-19) has rapidly spread from its starting point in Wuhan, China. As of February 23, 2020, a total of 32 countries and territories have reported 78,811 cases (98% in China) and 2462 deaths [1]. The international scientific community is in a race against time. Researchers across the globe are collaborating to develop antivirals and vaccines to contain the spread of 2019 novel coronavirus (SARS-CoV-2).

Elsevier’s Tim Miller’s article in World Pharma Today provides a insightful lens into the reality behind the complexities of implementing artificial intelligence into the R&D cycle. While great strides have been made, the runway to realize the potential is a long one and there are many exciting discoveries left to be made and obstacles to overcome.

Elsevier held a prominent place at last weeks Bio-IT World conference, recognized as a finalist for both ‘Best of Show’ as well as ‘People’s Choice. Highlighted was Elsevier’s Entellect, a new platform for integrated data management in pharmaceutical and life sciences industries.